Article
Application of hepatic cytochrome b5/P450 reductase null (HBRN) mice to study the role of cytochrome b5 in the cytochrome P450-mediated bioactivation of the anticancer drug ellipticine.
Toxicology and applied pharmacology - 1 Mar 2019
Reed Lindsay, Indra Radek, Mrizova Iveta, Moserova Michaela, Schmeiser Heinz H, Wolf C Roland, Henderson Colin J, Stiborova Marie, Phillips David H, Arlt Volker M
Abstract excerpt
The anticancer drug ellipticine exerts its genotoxic effects after metabolic activation by cytochrome P450 (CYP) enzymes. The present study has examined the role of cytochrome P450 oxidoreductase (POR) and cytochrome b5 (Cyb5), electron donors to P450 enzymes, in the CYP-mediated metabolism and disposition of ellipticine in vivo. We used Hepatic Reductase Null (HRN) and Hepatic Cytochrome b5/P450 Reductase Null...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
